Loading clinical trials...
Loading clinical trials...
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Conditions
Interventions
ADCT-602
Locations
2
United States
City of Hope Comprehensive Cancer
Monrovia, California, United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
August 24, 2018
Primary Completion Date
November 6, 2025
Completion Date
November 6, 2025
Last Updated
December 12, 2025
NCT05007873
NCT02997761
NCT02689440
NCT04722848
NCT07356960
NCT00254423
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions